Complete financial analysis of Aileron Therapeutics, Inc. (ALRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aileron Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Battery Age Minerals Ltd (BM8.AX) Income Statement Analysis – Financial Results
- Nanoveu Limited (NVU.AX) Income Statement Analysis – Financial Results
- Al Rajhi Company for Cooperative Insurance (8230.SR) Income Statement Analysis – Financial Results
- Pulike Biological Engineering, Inc. (603566.SS) Income Statement Analysis – Financial Results
- MOBILE INFRASTRUCTURE CORP (MBIC) Income Statement Analysis – Financial Results
Aileron Therapeutics, Inc. (ALRN)
About Aileron Therapeutics, Inc.
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22.35M |
| Cost of Revenue | 119.00K | 169.00K | 121.00K | 163.00K | 155.00K | 218.00K | 95.00K | 232.00K | 325.00K | 9.33M | 12.23M |
| Gross Profit | -119.00K | -169.00K | -121.00K | -163.00K | -155.00K | -218.00K | -95.00K | -232.00K | -325.00K | -9.33M | 10.12M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 45.29% |
| Research & Development | 3.99M | 17.97M | 17.01M | 11.17M | 17.66M | 18.45M | 14.24M | 10.28M | 7.83M | 9.33M | 12.23M |
| General & Administrative | 11.36M | 9.68M | 9.60M | 9.33M | 12.29M | 13.45M | 8.77M | 7.89M | 5.06M | 6.70M | 6.84M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.36M | 9.68M | 9.60M | 9.33M | 12.29M | 13.45M | 8.77M | 7.89M | 5.06M | 6.70M | 6.84M |
| Other Expenses | 928.00K | 318.00K | 441.00K | -800.00K | 0.00 | 0.00 | 0.00 | -18.17M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 16.28M | 27.65M | 26.61M | 20.50M | 29.96M | 31.90M | 23.01M | 18.17M | 12.89M | 6.70M | 6.84M |
| Cost & Expenses | 16.28M | 27.65M | 26.61M | 20.50M | 29.96M | 31.90M | 23.01M | 18.17M | 12.89M | 16.03M | 19.07M |
| Interest Income | 0.00 | 0.00 | 0.00 | 587.00K | 355.00K | 404.00K | 46.00K | 13.00K | 10.00K | 6.00K | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation & Amortization | 119.00K | 169.00K | 121.00K | 163.00K | 155.00K | 218.00K | 95.00K | 232.00K | 325.00K | 585.00K | 774.00K |
| EBITDA | -15.61M | -27.48M | -26.48M | -20.33M | -29.80M | -31.33M | -23.01M | -17.94M | -12.57M | -15.44M | 4.06M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 18.16% |
| Operating Income | -16.28M | -27.65M | -26.61M | -20.50M | -29.96M | -31.90M | -23.01M | -18.17M | -12.89M | -16.03M | 3.28M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14.69% |
| Total Other Income/Expenses | 544.00K | 318.00K | 441.00K | -661.00K | 587.00K | 355.00K | 404.00K | 46.00K | 13.00K | 10.00K | 6.00K |
| Income Before Tax | -15.73M | -27.33M | -26.21M | -21.16M | -29.37M | -31.55M | -22.60M | -18.12M | -12.88M | -16.02M | 3.29M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14.72% |
| Income Tax Expense | 0.00 | -318.00K | -441.00K | 661.00K | -587.00K | 355.00K | 34.00K | 0.00 | 0.00 | 43.00K | 3.10M |
| Net Income | -15.73M | -27.01M | -25.76M | -21.82M | -28.78M | -31.55M | -22.60M | -18.12M | -12.88M | -16.07M | 194.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.87% |
| EPS | -3.42 | -5.95 | -5.80 | -12.52 | -23.46 | -42.81 | -60.74 | -33.21 | -23.60 | -845.63 | 10.21 |
| EPS Diluted | -3.42 | -5.95 | -5.80 | -12.52 | -23.46 | -42.81 | -60.74 | -33.21 | -23.60 | -844.96 | 10.85 |
| Weighted Avg Shares Out | 4.60M | 4.54M | 4.44M | 1.74M | 1.23M | 736.91K | 372.15K | 545.72K | 545.72K | 19.00K | 19.00K |
| Weighted Avg Shares Out (Dil) | 4.60M | 4.54M | 4.44M | 1.74M | 1.23M | 736.91K | 372.15K | 545.72K | 545.72K | 19.02K | 17.89K |
Is Aileron Therapeutics, Inc. (ALRN) Stock Outpacing Its Medical Peers This Year?
Here is how Aileron Therapeutics, Inc. (ALRN) and Becton Dickinson (BDX) have performed compared to their sector so far this year.
Aileron Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, is pleased to announce that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer,...
Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924's Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity
-- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agent for patients with p53-mutated cancer undergoing chemotherapy -- -- Preclinical data demonstrated ALRN-6924's activation of p21-induced cell cycle arrest in murine bone marrow cells and epithelial mucosa cells...
Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021
BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced it will present new preclinical data at the upcoming AACR-NCI-EORTC International Conference...
Aileron Stock Is Trading Lower After Data Presentation For Chemoprotective Agent
Aileron Therapeutics Inc (NASDAQ: ALRN) presented new clinical data at the European Society of Medical Oncology ( ESMO21 ) Virtual Congress 2021 for ALRN-6924, a chemoprotective agent. Aileron is developing ALRN-6924 to selectively protect healthy cells in patients with cancers that harbor p53...
Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924's Best-in-Class Potential as a Chemoprotective Agent
BOSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today presented new clinical data at the European Society of Medical Oncology (ESMO) Virtual...
Aileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprotective Agent ALRN-6924
BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced two upcoming poster presentations at the European Society of Medical Oncology (ESMO)...
Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference
BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give...
Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting
BOSTON, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced a poster presentation showcasing initial findings from its ongoing study of ALRN-6924...
Source: https://incomestatements.info
Category: Stock Reports